Status:

COMPLETED

Extension Study of the Efficacy of the GSK 580299 Vaccine in Japanese Women Vaccinated in the Primary NCT00316693 Study

Lead Sponsor:

GlaxoSmithKline

Conditions:

Infections, Papillomavirus

Eligibility:

FEMALE

20-25 years

Phase:

PHASE3

Brief Summary

This extension study is conducted to assess the efficacy of the GSK 580299 vaccine against cervical intraepithelial neoplasia (CIN) lesions, cervical cancer and cytological abnormalities associated wi...

Eligibility Criteria

Inclusion

  • Subjects who the investigator believes that they can and will comply with the requirements of the protocol;
  • Written informed consent obtained from the subject prior to enrolment in the extension study;
  • A subject previously vaccinated in the NCT00316693 study.
  • Subjects who showed, at the last NCT00316693 study visit (at Month 24) willingness to participate in this extension study.

Exclusion

  • Use of any HPV vaccine other than the one administered in the NCT00316693 study;
  • Use of any investigational or non-registered product other than the study vaccine since last NCT00316693 study visit, or planned use during the study period;
  • Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product;
  • Subjects who were diagnosed high grade or missing cytology at Month 0 in the NCT00316693 study;
  • Pregnant females and females who were pregnant less than 3 months ago.

Key Trial Info

Start Date :

June 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

February 1 2011

Estimated Enrollment :

752 Patients enrolled

Trial Details

Trial ID

NCT00929526

Start Date

June 1 2009

End Date

February 1 2011

Last Update

October 20 2016

Active Locations (13)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 4 (13 locations)

1

GSK Investigational Site

Aomori, Japan, 036-8003

2

GSK Investigational Site

Fukui, Japan, 910-0858

3

GSK Investigational Site

Hiroshima, Japan, 733-0813

4

GSK Investigational Site

Hiroshima, Japan, 734-0036